Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis

被引:131
作者
Steele, Russell [1 ]
Hudson, Marie
Lo, Ernest
Baron, Murray
机构
[1] Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
基金
加拿大健康研究院;
关键词
SCLERODERMA; CYCLOPHOSPHAMIDE; VERIFICATION; IMPUTATION; PLACEBO;
D O I
10.1002/acr.21583
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To develop a clinical decision rule to predict the presence of interstitial lung disease (ILD) in systemic sclerosis (SSc; scleroderma) and to estimate the prevalence of SSc-ILD. Methods. Patient data were extracted from the Canadian Scleroderma Research Group registry. Three algorithms for the clinical decision rule were considered based on lung auscultation, chest radiography (CXR), and % predicted forced vital capacity (FVC). High-resolution computed tomography (HRCT) scans were used as the gold standard to determine the diagnostic properties of the 3 algorithms. Multiple imputation was used to impute HRCT data when missing, thereby avoiding bias due to differential referral for HRCT. Results. This study included 1,168 patients. Of the patients with HRCT scans, 65% had evidence of ILD, compared to 26% by physical examination and 22% by CXR. The FVC of those who did not have HRCT was 8.8% greater than those who did (95% confidence interval [95% CI] 6.0-11.6%). Algorithm A, which identified the presence of ILD based on crackles on lung auscultation and/or findings on CXR, had a likelihood ratio of 3.9, compared to 3.2 for Algorithm B (which included patients with FVC < 70%) and 2.2 for Algorithm C (which included patients with FVC < 80%). The prevalence of ILD in the cohort was estimated to be 52% (95% CI 46-59%). Conclusion. We developed a simple clinical decision rule to predict SSc-ILD with good test characteristics. The prevalence of ILD in a large, unselected SSc cohort was estimated to be 52%.
引用
收藏
页码:519 / 524
页数:6
相关论文
共 23 条
[1]   LUNG-FUNCTION TESTING - SELECTION OF REFERENCE VALUES AND INTERPRETATIVE STRATEGIES [J].
不详 .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (05) :1202-1218
[2]   Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort [J].
Assassi, Shervin ;
Sharif, Roozbeh ;
Lasky, Robert E. ;
McNearney, Terry A. ;
Estrada-Y-Martin, Rosa M. ;
Draeger, Hilda ;
Nair, Deepthi K. ;
Fritzler, Marvin J. ;
Reveille, John D. ;
Arnett, Frank C. ;
Mayes, Maureen D. .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (05)
[3]   The relationship of dyspnoea to function and quality of life in systemic sclerosis [J].
Baron, M. ;
Sutton, E. ;
Hudson, M. ;
Thombs, B. ;
Markland, J. ;
Pope, J. ;
Robinson, D. ;
Jones, N. ;
Docherty, P. ;
Abu-Hakima, M. ;
LeClercq, S. ;
Smith, D. ;
Mathieu, J-P .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (05) :644-650
[4]   ASSESSMENT OF DIAGNOSTIC-TESTS WHEN DISEASE VERIFICATION IS SUBJECT TO SELECTION BIAS [J].
BEGG, CB ;
GREENES, RA .
BIOMETRICS, 1983, 39 (01) :207-215
[5]  
Centre for Evidence Based Medicine, 2009, INT NOM
[6]   PATHOLOGIC OBSERVATIONS IN SYSTEMIC SCLEROSIS (SCLERODERMA) - A STUDY OF 58 AUTOPSY CASES AND 58 MATCHED CONTROLS [J].
DANGELO, WA ;
FRIES, JF ;
MASI, AT ;
SHULMAN, LE .
AMERICAN JOURNAL OF MEDICINE, 1969, 46 (03) :428-+
[7]   Afuican-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease [J].
Greidinger, EL ;
Flaherty, KT ;
White, B ;
Rosen, A ;
Wigley, FM ;
Wise, RA .
CHEST, 1998, 114 (03) :801-807
[8]   Multiple imputation for correcting verification bias [J].
Harel, Ofer ;
Zhou, Xiao-Hua .
STATISTICS IN MEDICINE, 2006, 25 (22) :3769-3786
[9]   Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population [J].
Hinchcliff, Monique ;
Fischer, Aryeh ;
Schiopu, Elena ;
Steen, Virginia D. .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (10) :2172-2179
[10]   A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma [J].
Hoyles, Rachel K. ;
Ellis, Ross W. ;
Wellsbury, Jessica ;
Lees, Belinda ;
Newlands, Pauline ;
Goh, Nicole S. L. ;
Roberts, Christopher ;
Desai, Sujal ;
Herrick, Ariane L. ;
McHugh, Neil J. ;
Foley, Noeleen M. ;
Pearson, Stanley B. ;
Emery, Paul ;
Veale, Douglas J. ;
Denton, Christopher P. ;
Wells, Athol U. ;
Black, Carol M. ;
du Bois, Roland M. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3962-3970